Summary
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Symptomatic Vitreomacular Adhesion in 9 Major Markets
Symptomatic Vitreomacular adhesion (VMA) is a rare macular condition caused by an incomplete posterior vitreous detachment from the retina, located at the back of the eye, with remaining vitreomacular attachment and unperturbed foveal morphologic features. It is almost always the result of normal vitreous aging, and is termed symptomatic VMA leading to vitreomacular traction because with loss of vitreous volume, these areas of VMA exert a “pulling force” on the macula, causing other pathologic conditions.
This report provides the current prevalent population for symptomatic VMA across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of VMA have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for VMA include:
• Decreased visual acuity
• Retinal distortion and disruption
• Post-menopause (females)
• Macular oedema
• Macular hole
• Myopia
• Diabetes
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global symptomatic VMA’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of symptomatic VMA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on symptomatic VMA’s prevalent population.
• Identify sub-populations within symptomatic VMA which require treatment.
• Gain an understanding of the specific markets that have the largest number symptomatic VMA patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Symptomatic VMA
• Main Complications and Features of Symptomatic Vitreomacular Patients
o The presence of Symptomatic VMA in Age-related Macular Degeneration (AMD)
o Diameter of adhesion in Symptomatic VMA
o Prevalence of Co-morbidities in Symptomatic VMA Patients
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables & Figures
• Prevalence of Symptomatic VMA, total (000s)
• Prevalence of Symptomatic VMA, males (000s)
• Prevalence of Symptomatic VMA, females (000s)
• Symptomatic VMA by morphology, total (000s)
• Prevalence of Isolated Symptomatic VMA and Concurrent VMA, total (000s)
• Focal and Broad Symptomatic VMA, total (000s)
• Prevalence of Decreased VA in Symptomatic VMA patients, total (000s)
• Prevalence of RD and Disruption in Symptomatic VMA patients, total (000s)
• Prevalence of DR in Symptomatic VMA patients, total (000s)
• Prevalence of Macular Oedema in Symptomatic VMA patients, total (000s)
• Prevalence of DME in Symptomatic VMA patients, total (000s)
• Prevalence of Macular Hole in Symptomatic VMA patients, total (000s)
• Abbreviations and Acronyms used in the Report
• USA Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• USA Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• France Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• France Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• Germany Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• Germany Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• Italy Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• Italy Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• Spain Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• Spain Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• Brazil Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• Brazil Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• Japan Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• Japan Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
• India Prevalence of Symptomatic VMA by 5-yr age cohort, males (000s)
• India Prevalence of Symptomatic VMA by 5-yr age cohort, females (000s)
